SMI (Starch Medical Inc.) is a San Jose, CA based medical device company engaged in the design, manufacture and sale of innovative, absorbable surgical hemostats synthesized from Absorbable Modified Polymers (AMP™), a proprietary, patent pending technology. SMI has organized a global distribution network for the marketing and sales of PerClot™ Polysaccharide Hemostatic System (PHS), which launched in the 4th Quarter, 2008. The SealFoam™ absorbable polysaccharide hemostat was awarded a CE mark in December, 2008 and is currently in clinical evaluation studies.

 

SMI was founded by surgeons and medical device industry executives who concentrated their expertise to develop new, absorbable surgical hemostats to satisfy clinically significant bleeding challenges.  In collaboration with well-known polymer engineers, biomaterial scientists and surgeons, SMI has developed a breakthrough hemostatic technology based on engineered, polymeric, modified starch particles.  AMP™ particles accelerate significantly the physiologic clotting process and exhibit the requisite features of safety, efficacy and absorbability.

 

In 2008, SMI established an ISO 13485 certified Class 7 (Class 10,000) clean room to manufacture its polymeric polysaccharide hemostats. Starch Medical has a registered ISO 13485 quality control system and is committed to delivering quality products and services in strict compliance with all international standards. CE mark for the PerClot™ Polysaccharide Hemostatic System and the SuperClot™  Absorbable Polysaccharide Hemostat was awarded in June, 2008.  SMI has patents pending for its AMP™  technology in the United States and other major markets.